title: [Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease].
abstract: Invasive fungal disease (IFD) causes a high morbidity and mortality in patients with hematological malignancies. Reactivation of IFD after chemotherapy or hematopoietic stem cell transplantation (HSCT) is very common and associated with poor prognosis. Secondary antifungal prophylaxis (SAP) is effective in preventing IFD recurrence. With effective SAP, a history of IFD is not an absolute contraindication to allogeneic HSCT or continuation of high-dose chemotherapy. In recent years, a variety of antifungal drugs such as voriconazole, itraconazole, AmB and caspofungin have been found to be effective for SAP. However, its management during granulocytopenia and immunosuppression remains challenging. This review summarizes the current status of SAP in patients with hematological malignancies.
authors.affiliation: Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing 100853, China.|Department of Hematology, 309 Hospital of Chinese People's Liberation Army, Beijing 100091, China.
authors.forename: Ming-Juan
authors.initials: MJ
authors.lastname: Liu
authors.affiliation: Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Huang
authors.affiliation: Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000935:Antifungal Agents; D019337:Hematologic Neoplasms; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D009181:Mycoses
chemical_list: D000935:Antifungal Agents